Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-30

Smart nanoparticle system for lung cancer application

Objective

"As a result of the research undertook in the MYCAP ERC project, Dr Martín del Valle’s team have developed a new smart nanoparticle for delivering cisplatin, which is the current lung cancer standard of care (SoC). In order to accelerate its market entry, the present “Proof of Concept” (PoC) project, named NANOSPART, will conduct in vitro validation of cisplatin nanoparticles through cell lines culture assays, as well as the technological optimization of the drug delivering system and the upper spray-based technology arisen from “MYCAP” ERC funded.
The work undertaken so far requires further investment in applied research, in order to turn the outputs shown above into a commercial proposition. The NANOSMART project will make an important contribution towards the future pre-clinical and clinical phases, and new key industrial applications.
Dr. Martín del Valle´s team have developed a new drug delivery system (DDS) for lung cancer treatment based on polymer nanoparticles, as a result of MYCAP project. Dr Martín del Valle now aims to progress this idea to PoC through the NANOSMART project, which has mainly three goals: defining the right chemical properties of these nanoparticles; determining the optimal dose of cisplatin-conjugates in relation to toxicity and efficacy parameters; In terms of expected outcomes, the project will contribute to meet critical market needs in lung cancer treatment. Globally, lung cancer is one of the most common types of cancer, with an estimated 1.2 million new cases being diagnosed every year. Despite the emergence of new treatments, 85% of lung cancer patients don’t survive, which is mainly due to metastatic disease . Because of the overall poor prognosis, new treatment strategies for lung cancer patients are urgently needed. Dr. Eva Martín del Valle and her team from University of Salamanca, are willing to address this issue with a new approach that utilises novel nanopartictechnology to deliver the current SoC (cisplatin)."

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

ERC-2012-PoC
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CSA-SA(POC) - Supporting action (Proof of Concept)

Host institution

UNIVERSIDAD DE SALAMANCA
EU contribution
€ 143 400,00
Address
CALLE PATIO DE ESCUELAS 1
37008 Salamanca
Spain

See on map

Region
Centro (ES) Castilla y León Salamanca
Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Beneficiaries (1)

My booklet 0 0